Shogo Shimizu

Kawaguchi, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Cyanoacrylate closure for arteriovenous fistula in the lower extremity with saphenous vein insufficiency.

Cyanoacrylate closure for arteriovenous fistula in the lower extremity with saphenous vein insufficiency.

Journal: Journal of vascular surgery cases and innovative techniques

Published: June 30, 2023

Correction to: Influence of CYP2C19 genotypes for the effect of 1‑month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12‑month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT‑2.

Correction to: Influence of CYP2C19 genotypes for the effect of 1‑month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12‑month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT‑2.

Journal: Cardiovascular intervention and therapeutics

Published: February 13, 2021

Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2.

Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2.

Journal: Cardiovascular intervention and therapeutics

Published: August 27, 2020

One-year clinical outcomes of patients with versus without acute coronary syndrome with 3-month duration of dual antiplatelet therapy after everolimus-eluting stent implantation.

One-year clinical outcomes of patients with versus without acute coronary syndrome with 3-month duration of dual antiplatelet therapy after everolimus-eluting stent implantation.

Journal: PloS one

Published: August 27, 2019

A novel method to align cells in a cardiac tissue-like construct fabricated by cell sheet-based tissue engineering.

A novel method to align cells in a cardiac tissue-like construct fabricated by cell sheet-based tissue engineering.

Journal: Journal of tissue engineering and regenerative medicine

Published: August 22, 2019

The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation.

The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation.

Journal: International journal of cardiology

Published: January 25, 2018

Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation.

Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation.

Journal: The Tohoku journal of experimental medicine

Published: December 02, 2016

One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial.

One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial.

Journal: Cardiovascular intervention and therapeutics

Published: September 14, 2015

Showing 1-8 of 8

Last Updated: 09/26/2026